Pharmaceutical Intermediates
- • Analgesics (59)
- • Anesthetics (52)
- • Anti-Addiction Agents (8)
- • Antibacterials (118)
- • Anticonvulsants (20)
- • Antidementia Agents (23)
- • Antidepressants (35)
- • Antiemetics (24)
- • Antifungals (24)
- • Antigout Agents (9)
- • Anti-inflammatory Agents (28)
- • Antimigraine Agents (21)
- • Antineoplastics (427)
- • Antiparasitics (11)
- • Antiparkinson Agents (28)
- • Antipsychotics (54)
- • Antispasticity Agents (12)
- • Antivirals (146)
- • Anxiolytics (16)
- • Blood Glucose Regulators (106)
- • Blood Products (61)
- • Cardiovascular Agents (179)
- • CNS Agents (22)
- • Dental and Oral Agents (8)
- • Dermatological Agents (19)
- • Electrolytes (15)
- • Gastrointestinal Agents (63)
- • Genetic/Enzyme Disorder (12)
- • Genitourinary Agents (47)
- • Immunological Agents (36)
- • Metabolic Bone Disease (6)
- • Ophthalmic Agents (476)
- • Respiratory Tract (51)
- • Skeletal Muscle Relaxants (5)
- • Sleep Disorder Agents (28)
- • Oled Material Intermediate (333)
- • Heterocyclic Compound (9764)
- • Bulk Drug Intermediates (17746)
Related News
-
China Releases 15th Five-Year Carbon-Peaking Action Plan, Pushing Coal Chemicals into a Mandatory Low-Carbon Upgrade Cycle
2026-07-16 -
Vera’s New Kidney Drug Wins FDA Approval, Carrying a $425,000 Annual Price
2026-07-14 -
Premium Global Chemical Sourcing Requests (16-19July, 2026)
2026-07-20 -
Premium Global Chemical Sourcing Requests (13-15July, 2026)
2026-07-16 -
Premium Global Chemical Sourcing Requests (9-13July, 2026)
2026-07-13 -
China's SBR Prices Rise Driven by Costs
2026-07-22
Genetic/Enzyme Disorder
N-Hydroxysuccinimide
(6066-82-6)-
Pharmaceutical Grade / 99%
-
Pharmaceutical Grade / 99%
-
Pharmaceutical Grade / 99%
-
Pharmaceutical Grade / 99%
Request for quotation , get quotes from more suppliers.
(+)-Phenylglycinol
(20989-17-7)-
Pharmaceutical Grade / 99%
-
Pharmaceutical Grade / 99%
-
Pharmaceutical Grade / 99%
-
Pharmaceutical Grade / 99%
Request for quotation , get quotes from more suppliers.
1,2-O-Isopropylidene-α-D-glucofuranose
(18549-40-1)-
Pharmaceutical Grade / 99%
-
Pharmaceutical Grade / 98%
-
Pharmaceutical Grade / 99%
-
Pharmaceutical Grade / 99%
Request for quotation , get quotes from more suppliers.
2,3,4,6-Tetrakis-O-(phenylmethyl)-D-glucopyranose
(4132-28-9)-
Pharmaceutical Grade / 99%
-
Pharmaceutical Grade / 99%
-
pharmaceutical grade / 99.9%
-
Pharmaceutical Grade / 99%
Request for quotation , get quotes from more suppliers.
1,4-Benzodioxan-6-carboxaldehyde
(29668-44-8)-
Pharmaceutical Grade / 99%
-
pharmaceutical grade / 98%
-
Industrial Grade, Feed Grade, Food Grade, Pharma Grade / 99%
-
- / 99.00%
Request for quotation , get quotes from more suppliers.
Source Genetic/Enzyme Disorder Products Supply
-
Pharmaceutical grade / 99%
-
Pharmaceutical Grade / 99%
$50/ EXW
-
- / 99.00%
-
industrial Grade / 98%
Request for quotation , get quotes from more suppliers.
4-Cyclopentyl-1-piperazinamine
(61379-64-4)-
Industrial Grade / pharmaceutical grade / 99%
-
- / 99.00%
-
-
Request for quotation , get quotes from more suppliers.
-
Pharmaceutical Grade / 99%
-
Industrial Grade / pharmaceutical grade / 99%
-
- / 99.00%
-
industrial Grade / 98%
Request for quotation , get quotes from more suppliers.
-
Pharmaceutical Grade / 99%
-
- / 99.00%
-
Industrial Grade / 99.0%
-
Request for quotation , get quotes from more suppliers.
-
- / 99.00%
-
Industrial Grade / 99.0%
-
-
Industrial Grade / 99%
Request for quotation , get quotes from more suppliers.
More Information
Genetic/Enzyme Disorder Intermediates are essential raw materials used in the synthesis of drugs targeting genetic and metabolic conditions, including enzyme deficiencies, inherited disorders, and rare diseases. These intermediates provide the foundation for enzyme replacement therapies, metabolic modulators, and gene-targeted pharmaceuticals.
Common applications and types include:
• Enzyme replacement intermediates — for therapies addressing specific enzyme deficiencies.
• Metabolic disorder intermediates — used in the treatment of inborn errors of metabolism.
• Gene therapy intermediates — supporting the production of recombinant proteins or nucleic acid-based treatments.
• Cofactor and substrate intermediates — necessary for enzymatic activity and therapeutic formulation.
Frequently Asked Questions
A genetic enzyme disorder is a type of inherited metabolic condition caused by mutations in genes responsible for producing specific enzymes. These enzymes are essential for breaking down nutrients, building cellular components, or eliminating waste. When deficient or dysfunctional, toxic substances may accumulate or critical compounds may be lacking, leading to health complications. Examples include phenylketonuria (PKU), Gaucher disease, and Tay-Sachs disease.
Genetic enzyme disorders are typically diagnosed through a combination of clinical evaluation, biochemical testing (such as blood or urine analysis to detect abnormal metabolite levels), and genetic testing to identify specific gene mutations. Newborn screening programs in many countries also test for common enzyme deficiencies shortly after birth, enabling early intervention and management.
Symptoms of enzyme deficiency disorders vary widely depending on the specific enzyme affected but may include developmental delays, seizures, muscle weakness, organ enlargement (such as liver or spleen), poor weight gain, vomiting, and neurological deterioration. Some disorders present in infancy, while others may not become apparent until later in childhood or adulthood.
While many genetic enzyme disorders have no cure, several treatment options can help manage symptoms and slow disease progression. These include enzyme replacement therapy (ERT), substrate reduction therapy, dietary modifications (e.g., low-phenylalanine diet for PKU), chaperone therapy, and in some cases, bone marrow or stem cell transplantation. Early diagnosis and personalized care plans are critical for improving outcomes.
Families coping with a genetic enzyme disorder diagnosis should seek support from metabolic specialists, genetic counselors, and patient advocacy groups. Creating a multidisciplinary care team—including dietitians, neurologists, and therapists—can help manage medical and developmental needs. Additionally, connecting with other affected families and staying informed about emerging therapies can provide emotional support and practical guidance.